Best practice guidelines on first-line laboratory testing for porphyria

Jacqueline Woolf1, Joanne T Marsden2, Timothy Degg3

  • 11 Department of Medical Biochemistry and Immunology, University Hospital of Wales, Cardiff, UK.

Insights

Porphyrias are rare genetic disorders of heme biosynthesis. Early diagnosis of acute attacks and cutaneous porphyrias relies on prompt biochemical screening of urine and blood samples, crucial for effective management.

Area of Science:

  • Biochemistry
  • Genetics
  • Internal Medicine

Background:

  • Porphyrias are a group of inherited disorders affecting heme biosynthesis.
  • Clinical manifestations include acute neurovisceral attacks and sun-exposed skin disorders.
  • Accurate and timely diagnosis is essential for patient management and preventing complications.

Purpose of the Study:

  • To outline the diagnostic biochemical investigations for acute and cutaneous porphyrias.
  • To emphasize the importance of appropriate sample collection and timely laboratory analysis.
  • To guide clinicians on referral pathways for complex cases.

Main Methods:

  • Urine porphobilinogen (PBG) quantitation using validated methods (ion-exchange resin or LC-MS) during acute attacks.
  • Measurement of total urine porphyrins (TUP) and plasma porphyrins via fluorescence emission spectroscopy.
  • Analysis of whole blood and fecal porphyrins for specific porphyria types, including protoporphyria.

Main Results:

  • Urgent PBG testing within 24 hours of sample receipt is recommended for acute attacks.
  • Specific porphyrin profiles in urine, plasma, blood, and feces differentiate various porphyria types.
  • Latent porphyria or family history investigations require specialist laboratory consultation.

Conclusions:

  • Prompt biochemical screening of protected samples is critical for diagnosing porphyrias.
  • Adherence to recommended testing protocols ensures accurate and efficient diagnosis.
  • Specialist consultation is advised for complex diagnostic scenarios and family screening.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
248
Serum Laboratory Studies, Stool Test, Breath Test01:30

Serum Laboratory Studies, Stool Test, Breath Test

Gastrointestinal (GI) diagnostic studies are pivotal in confirming, ruling out, diagnosing, or staging various diseases, including cancers. Following diagnosis, allocating time for discussions with the patient and providing informational resources is crucial. Diagnostic assessments of the GI tract often occur in outpatient settings like endoscopy suites or GI labs. Preparation for these tests may include dietary restrictions, fasting, liquid bowel preparations, laxatives, enemas, and the...
1.0K
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
99
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
312